A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
Public ClinicalTrials.gov record NCT03347110. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
Study identification
- NCT ID
- NCT03347110
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Enrollment
- 184 participants
Conditions and interventions
Conditions
Interventions
- Bimekizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 21, 2017
- Primary completion
- Oct 28, 2020
- Completion
- Oct 28, 2020
- Last update posted
- Nov 30, 2023
2017 – 2020
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pa0009 025 | Lexington | Kentucky | 40504 | — |
| Pa0009 003 | Hagerstown | Maryland | 21502 | — |
| Pa0009 011 | Lansing | Michigan | 48910 | — |
| Pa0009 028 | Rochester | New York | 14642 | — |
| Pa0009 014 | Portland | Oregon | 97239 | — |
| Pa0009 001 | Duncansville | Pennsylvania | 16635 | — |
| Pa0009 012 | Johnston | Rhode Island | 02919 | — |
| Pa0009 004 | Charleston | South Carolina | 29406 | — |
| Pa0009 010 | Jackson | Tennessee | 38305 | — |
| Pa0009 006 | Dallas | Texas | 75231 | — |
| Pa0009 013 | Mesquite | Texas | 75150 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03347110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 30, 2023 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03347110 live on ClinicalTrials.gov.